MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR

Molecular Cancer Therapeutics

Volumn 12, Issue 7, 2013, Pages 1202-1212

  Cheng, Yun Ching ^a   Liou, Jing Ping ^d   Kuo, Ching Chuan ^a   Lai, Wen Yang ^a   Shih, Kuang Hsing ^e   Chang, Chi Yen ^a   Pan, Wen Yu ^a   Tseng, Joseph T ^b   Chang, Jang Yang ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

7 INDOLINE 1 BENZENE SULFONAMIDE; ANTINEOPLASTIC AGENT; COLCHICINE; HUR PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MPT 0B 098; PACLITAXEL; SULFONAMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CAPILLARY; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84880049488     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0778     Document Type: Article

References (44)

1. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47. (Pubitemid 37328806)
2. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790-7.
3. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307. (Pubitemid 37069660)
4. Chan DA, Sutphin PD, Yen SE, Giaccia AJ. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2005;25:6415-26. (Pubitemid 41023218)
5. Tian YM, Yeoh KK, Lee MK, Eriksson T, Kessler BM, Kramer HB, et al. Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem 2011;286:13041-51.
6. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37. (Pubitemid 351744964)
7. Akhmanova A, Steinmetz MO. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008;9:309-22. (Pubitemid 351430849)
8. Akhmanova A, Hoogenraad CC. Microtubule plus-end-tracking proteins: mechanisms and functions. Curr Opin Cell Biol 2005;17:47-54. (Pubitemid 40138087)
9. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95.
10. Kiselyov A, Balakin KV, Tkachenko SE, Savchuk N, Ivachtchenko AV. Recent progress in discovery and development of antimitotic agents. Anticancer Agents Med Chem 2007;7:189-208. (Pubitemid 46403584)
11. Shi Q, Chen K, Morris-Natschke SL, Lee KH. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 1998;4:219-48. (Pubitemid 28277446)
12. Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, et al. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer 2006;107:1852-8. (Pubitemid 44582955)
13. Tanaka Y, Fujiwara K, Tanaka H, Maehata K, Kohno I. Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. Int J Gynecol Cancer 2004;14:616-20. (Pubitemid 39062916)
14. Raitanen M, Rantanen V, Kulmala J, Pulkkinen J, Klemi P, Grenman S, et al. Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines. Int J Cancer 2002;97:853-7. (Pubitemid 34106344)
15. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009;15:2594-601.
16. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005;65:9021-8. (Pubitemid 41377394)
17. Carbonaro M, O'Brate A, Giannakakou P. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol 2011;192:83-99.
18. Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Wu JS, et al. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 2010;53:2309-13.
19. Finlay GJ, Baguley BC, Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984;139:272-7. (Pubitemid 14079980)
20. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004;64:4621-8.
21. Liao WL, Wang WC, Chang WC, Tseng JT. The RNA-binding protein HuR stabilizes cytosolic phospholipase A2alpha mRNA under inter-leukin- 1beta treatment in non-small cell lung cancer A549 Cells. J Biol Chem 2011;286:35499-508.
22. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413 -50.
23. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75. (Pubitemid 38340305)
24. Hait WN, Hambley TW. Targeted cancer therapeutics. Cancer Res 2009;69:1263-7.
25. Kuppens IE. Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 2006;1:57 -70.
26. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1alpha and cancer therapy. Recent Results Cancer Res 2010;180:15-34.
27. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-82. (Pubitemid 38235619)
28. Creighton-Gutteridge M, Cardellina JH II, Stephen AG, Rapisarda A, Uranchimeg B, Hite K, et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 2007;13:1010-8. (Pubitemid 46340380)
29. Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1alpha and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis 2012;15:15-27.
30. Lee JM, Lee WH, Kay HY, Kim ES, Moon A, Kim SG. Hemin, an iron-binding porphyrin, inhibits HIF-1alpha induction through its binding with heat shock protein 90. Int J Cancer 2012;130:716-27.
31. 2-independent proteolysis of HIF-1alpha via HSP90/70. PLoS One 2009;4:e7332.
32. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 2009;69:1624- 32.
33. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 2008;283:16309 -19.
34. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008;7:3598- 608.
35. Masuda K, Abdelmohsen K, Gorospe M. RNA-binding proteins implicated in the hypoxic response. J Cell Mol Med 2009;13:2759-69.
36. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001;58:266- 77.
37. Pryzbylkowski P, Obajimi O, Keen JC. Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat 2008;111:15- 25.
38. Kim HH, Yang X, Kuwano Y, Gorospe M. Modification at HuR(S242) alters HuR localization and proliferative influence. Cell Cycle 2008;7:3371-7.
39. Kim HH, Abdelmohsen K, Lal A, Pullmann R Jr, Yang X, Galban S, et al. Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev 2008;22:1804-15. (Pubitemid 351915505)
40. Doller A, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, Eberhardt W. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell 2007;18:2137-48. (Pubitemid 46911365)
41. Li H, Park S, Kilburn B, Jelinek MA, Henschen-Edman A, Aswad DW, et al. Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. J Biol Chem 2002;277:44623-30. (Pubitemid 36159051)
42. Doller A, Pfeilschifter J, Eberhardt W. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell Signal 2008;20:2165-73.
43. Kim HH, Gorospe M. Phosphorylated HuR shuttles in cycles. Cell Cycle 2008;7:3124-6.
44. Suginta W, Karoulias N, Aitken A, Ashley RH. Chloride intracellular channel protein CLIC4 (p64H1) binds directly to brain dynamin I in a complex containing actin, tubulin and 14-3-3 isoforms. Biochem J 2001;359:55-64. (Pubitemid 32939207)